Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 604-045-2 | CAS number: 137862-53-4
PBT assessment
Administrative data
PBT assessment: overall result
- Name:
- (2S)-3-Methyl-2-[N-({2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1-biphenyl]-4-yl}methyl)pentanamido]butanoic acid
- Type of composition:
- legal entity composition of the substance
- State / form:
- solid: particulate/powder
- Reference substance:
- (2S)-3-Methyl-2-[N-({2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1-biphenyl]-4-yl}methyl)pentanamido]butanoic acid
- PBT status:
- the substance is not PBT / vPvB
- Justification:
The substance is not P/vP:
Chronic aquatic toxicity: not classified
The substance is not B/vB:
The substance has low logKow value (1.2) and is not of greater concern because it has low potential to bio-concentrate in living organisms.
The substance is not T:
Post-Marketing Experience in Human
In addition to the safety experience gained from clinical trials, analysis of adverse event reports received from the market since the first introduction in 1996 has revealed very rare cases of angioedema, rash, pruritus, and other hypersensitivity/allergic reactions including serum sickness and vasculitis. Very rare cases of impaired renal function have also been reported. In addition, myalgia was observed as a rare adverse event with valsartan in a Prescription-Event-Monitoring study of around 13,000 patients in England [CRD-49]. Another study of monitoring adverse events in England reported that dyspnea was one of the most commonly reported events in association with valsartan. Based on post-marketing reports, several European countries have included the occurrence of very rare cases of bleeding and thrombocytopenia in association with valsartan into the local product information. Based on post-marketing reports, hyponatremia was added to the local product information in the EU.
Exposure in number of patient treatment years was calculated on the basis of sales data assuming an average daily dose of one tablet per day per patient. Total exposure to valsartan until 30 Apr 2014 is approximately 95 million patient treatment years for adults and 28,654 patient treatment years for pediatric use based on the amount of valsartan tablets sold.
Reference
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
